Vertex Pharmaceuticals EVP Sells $324,881 in Stock

Edward Morrow Atkinson III reduces his stake in the biotech company by 3.5%

Mar. 3, 2026 at 8:23am

Got story updates? Submit your updates here. ›

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Executive Vice President Edward Morrow Atkinson III sold 668 shares of the company's stock on February 25th, 2026. The shares were sold at an average price of $486.35, resulting in a total transaction value of $324,881.80. Following the sale, Atkinson still owns 18,432 shares in the company, valued at approximately $8,964,403.20.

Why it matters

Insider transactions, such as stock sales by company executives, can provide insights into management's views on the company's prospects. Atkinson's sale represents a 3.5% reduction in his Vertex Pharmaceuticals holdings, which could signal that he believes the stock is overvalued or that he wants to diversify his personal investments.

The details

The transaction was disclosed in a legal filing with the SEC. Vertex Pharmaceuticals is a Boston-based biotechnology company focused on developing therapies for serious diseases, particularly cystic fibrosis. The company's portfolio of CFTR modulators has transformed standards of care for many people with the disease.

  • The stock sale occurred on Wednesday, February 25th, 2026.

The players

Edward Morrow Atkinson III

Executive Vice President at Vertex Pharmaceuticals Incorporated.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

Insider transactions can provide valuable insights into a company's prospects, and Atkinson's sale of Vertex Pharmaceuticals stock could signal that he believes the stock is overvalued or that he wants to diversify his personal investments. However, without additional context, it's difficult to draw definitive conclusions about the company's future performance.